{"resourceType":"Evidence","id":"example-quoted-source","extension":[{"url":"http://hl7.org/fhir/StructureDefinition/structuredefinition-wg","valueCode":"cds"}],"title":"Quoted Source: Prevalence of PASC at 30 days","status":"active","publisher":"HL7 International / Clinical Decision Support","contact":[{"telecom":[{"system":"url","value":"http://www.hl7.org/Special/committees/dss"}]}],"description":"An example of using the relatedArtifact element to quote a line of text from the evidence source.","variableDefinition":[{"description":"People with a history of COVID-19 who were not hospitalized (Arizona CoVHORT)","variableRole":"population"},{"description":"Post-acute sequelae of COVID-19","variableRole":"outcome"}],"studyDesign":[{"coding":[{"system":"https://fevir.net/sevco","code":"SEVCO:01002","display":"Observational research"},{"system":"https://fevir.net/sevco","code":"SEVCO:01028","display":"Longitudinal data collection"}]}],"statistic":[{"description":"Prevalence 68.7% (95% Confidence interval 63.4% to 73.9%)","statisticType":{"coding":[{"system":"https://fevir.net/resources/CodeSystem/27270","code":"STATO:0000412","display":"prevalence"}]},"quantity":{"value":68.7,"unit":"%","system":"http://unitsofmeasure.org","code":"%"},"attributeEstimate":[{"description":"95% Confidence interval 63.4% to 73.9%","type":{"coding":[{"system":"https://fevir.net/resources/CodeSystem/27270","code":"TBD:0000059","display":"Confidence interval"}]},"level":0.95,"range":{"low":{"value":63.4,"unit":"%","system":"http://unitsofmeasure.org","code":"%"},"high":{"value":73.9,"unit":"%","system":"http://unitsofmeasure.org","code":"%"}}}]}]}
{"resourceType":"Evidence","id":"example-stroke-3-4half-alteplase-vs-no-alteplase-mRS0-2","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\n      \n      \u003cp\u003e\n        \u0026quot;Effect of Alteplase vs No alteplase on mRS 0-2 at 90 days in Stroke 3-4.5 hours prior\u0026quot; is a comparative effect estimate.\n      \u003c/p\u003e\n\t\n    \u003c/div\u003e"},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/structuredefinition-wg","valueCode":"cds"}],"url":"http://hl7.org/fhir/Evidence/example-stroke-3-4half-alteplase-vs-no-alteplase-mRS0-2","identifier":[{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113883.4.642.10.3"}],"name":"EffectOfAlteplaseVsNoAlteplaseOnMRS02At90DaysInStroke345HoursPrior","title":"Effect of Alteplase vs No alteplase on mRS 0-2 at 90 days in Stroke 3-4.5 hours prior","status":"draft","publisher":"HL7 International / Clinical Decision Support","contact":[{"telecom":[{"system":"url","value":"http://www.hl7.org/Special/committees/dss"}]}],"relatesTo":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/artifact-relationship-type","code":"cites","display":"Cites"}]},"targetMarkdown":"Figure 2 Lees 2016 \u003cb\u003eCitation:\u003c/b\u003e Lees KR, Emberson J, Blackwell L, Bluhmki E, Davis SM, Donnan GA, et al; Stroke Thrombolysis Trialists’ Collaborators Group. Effects of alteplase for acute stroke on the distribution of functional outcomes: a pooled analysis of 9 trials. Stroke. 2016;47:2373-2379. PMID 27507856 \u003cb\u003eURL:\u003c/b\u003e https://doi.org/10.1161/STROKEAHA.116.013644"}],"description":"mRS 0-2 at 90 days Odds Ratio 1.2 for Alteplase vs. No Alteplase in patients with acute ischemic stroke 3-4.5 hours prior","variableDefinition":[{"variableRole":"population","observed":{"reference":"EvidenceVariable/Stroke-Thrombolysis-Trialists-2014-2016-IPD-MA-Cohort","type":"EvidenceVariable","display":"Stroke Thrombolysis Trialists’ 2014-2016 IPD-MA Cohort"},"intended":{"reference":"Group/AcuteIschemicStroke3-4halfHours","type":"Group","display":"stroke at 3-4.5 hours"},"directnessMatch":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/directness","code":"moderate","display":"Moderate quality match between observed and intended variable"}]}},{"variableRole":"outcome","observed":{"reference":"EvidenceVariable/example-mRS0-2-at-90days","type":"EvidenceVariable","display":"mRS 0-2 at 90 days"},"intended":{"reference":"EvidenceVariable/example-alive-independent-90day","type":"EvidenceVariable","display":"Alive and not functionally dependent at 90 days"}},{"variableRole":"exposure","comparatorCategory":"No Alteplase","observed":{"reference":"EvidenceVariable/example-group-assignment-alteplase-for-stroke-vs-no-alteplase","type":"EvidenceVariable","display":"Group Assignment: Alteplase for Stroke vs No Alteplase"}}],"synthesisType":[{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/synthesis-type","code":"IPD-MA","display":"individual patient data meta-analysis"}]}],"studyDesign":[{"coding":[{"system":"https://fevir.net/sevco","code":"SEVCO:01003","display":"randomized assignment"}]}],"statistic":[{"statisticType":{"coding":[{"system":"https://fevir.net/sevco","code":"STATO:0000182","display":"odds ratio"}]},"quantity":{"value":1.2},"sampleSize":{"numberOfStudies":9},"attributeEstimate":[{"description":"95% CI 1.06 to 1.3","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/attribute-estimate-type","code":"C53324","display":"Confidence interval"}]},"level":0.95,"range":{"low":{"value":1.06},"high":{"value":1.3}}}]}],"certainty":[{"description":"Very low certainty due to risk of bias, inconsistency, imprecision, and indirectness","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/certainty-type","code":"Overall","display":"Overall certainty"}]},"rating":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/certainty-rating","code":"very-low","display":"Very low quality"}]},"subcomponent":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/certainty-type","code":"PublicationBias","display":"Publication bias"}]},"rating":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/certainty-rating","code":"no-concern","display":"no serious concern"}]}},{"note":[{"text":"IST-3 had inconsistent results and contributed large proportion of data"}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/certainty-type","code":"Inconsistency","display":"Inconsistency"}]},"rating":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/certainty-rating","code":"serious-concern","display":"serious concern"}]}},{"note":[{"text":"results derived from figure with limited data reported to support the specific effect estimate; derived odds ratio in figure does not match results from rates of mRS 0-2 reported in Supplementary Figure 3b"}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/certainty-type","code":"Imprecision","display":"Imprecision"}]},"rating":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/certainty-rating","code":"serious-concern","display":"serious concern"}]}},{"note":[{"text":"resuts derived for 3 - 4.5 hours assume data from 0 - 6 hours is informative"}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/certainty-type","code":"Indirectness","display":"Indirectness"}]},"rating":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/certainty-rating","code":"serious-concern","display":"serious concern"}]}},{"note":[{"text":"results largely influenced by IST-3 trial which was unblinded and ECASS III which had baseline imbalances"}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/certainty-type","code":"RiskOfBias","display":"Risk of bias"}]},"rating":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/certainty-rating","code":"serious-concern","display":"serious concern"}]}}]}]}
{"resourceType":"Evidence","id":"example-stroke-no-alteplase-fatalICH","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\n      \n      \u003cp\u003e\n        \u0026quot;Risk of fatal ICH without alteplase for stroke\u0026quot; is a univariate risk estimate.\n      \u003c/p\u003e\n\t\n    \u003c/div\u003e"},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/structuredefinition-wg","valueCode":"cds"}],"url":"http://hl7.org/fhir/Evidence/example-stroke-no-alteplase-fatalICH","identifier":[{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113883.4.642.10.4"}],"name":"RiskOfFatalICHWithoutAlteplaseForStroke","title":"Risk of fatal ICH without alteplase for stroke","status":"draft","publisher":"HL7 International / Clinical Decision Support","contact":[{"telecom":[{"system":"url","value":"http://www.hl7.org/Special/committees/dss"}]}],"relatesTo":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/artifact-relationship-type","code":"cites","display":"Cites"}]},"targetMarkdown":"Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. \u003cb\u003eCitation:\u003c/b\u003e Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al;Stroke Thrombolysis Trialists\u0027 Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014 Nov 29;384(9958):1929-35 PMID 25106063 \u003cb\u003eURL:\u003c/b\u003e https://doi.org/10.1016/S0140-6736(14)60584-5"}],"description":"0.4% incidence of fatal intracranial hemorrhage within 7 days without alteplase in patients with acute ischemic stroke","variableDefinition":[{"variableRole":"population","observed":{"reference":"Group/Emberson-2014-IPD-MA-No-Alteplase-Cohort","type":"Group","display":"Emberson 2014 IPD-MA No Alteplase Cohort"},"intended":{"reference":"Group/AcuteIschemicStrokeTreatedWithoutAlteplase","type":"Group","display":"adults with acute ischemic stroke treated without alteplase"}},{"variableRole":"outcome","observed":{"reference":"EvidenceVariable/example-fatal-ICH-in-7-days","type":"EvidenceVariable","display":"fatal ICH"},"intended":{"reference":"EvidenceVariable/example-fatal-ICH-in-7-days","type":"EvidenceVariable","display":"fatal ICH"}}],"synthesisType":[{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/synthesis-type","code":"IPD-MA","display":"individual patient data meta-analysis"}]}],"studyDesign":[{"coding":[{"system":"https://fevir.net/sevco","code":"SEVCO:01003","display":"randomized assignment"}]}],"statistic":[{"statisticType":{"coding":[{"system":"https://fevir.net/sevco","code":"STATO:0000607","display":"proportion"}]},"quantity":{"value":0.00386298627},"numberOfEvents":13,"sampleSize":{"numberOfStudies":9,"numberOfParticipants":3365}}]}
{"resourceType":"Evidence","id":"example-statistic-model-include-if","meta":{"versionId":"9","lastUpdated":"2025-03-10T14:59:32.227Z","profile":["http://hl7.org/fhir/uv/ebm/StructureDefinition/statistic-model"]},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/structuredefinition-wg","valueCode":"cds"}],"url":"http://hl7.org/fhir/Evidence/example-statistic-model-include-if","identifier":[{"type":{"text":"FEvIR Object Identifier"},"system":"urn:ietf:rfc:3986","value":"https://fevir.net/FOI/346428","assigner":{"display":"Computable Publishing LLC"}}],"title":"Example of statistical analysis plan with different statistical test if non-normal distribution","status":"active","author":[{"name":"Brian S. Alper, MD, MSPH"}],"publisher":"HL7 International / Clinical Decision Support","contact":[{"telecom":[{"system":"url","value":"http://www.hl7.org/Special/committees/dss"}]}],"copyright":"https://creativecommons.org/licenses/by-nc-sa/4.0/","description":"This example uses the StatisticModelIncludeIf extension to represent the model characteristic of Welch\u0027s 2-sample t-test if the data is consistent with a normal distribution (based on Shapiro-Wilk test with p-value \u003e\u003d 0.05) and a Wilcoxon Mann-Whitney test if not.","variableDefinition":[{"description":"Adults with hypertension","variableRole":"population"},{"description":"Reversitol vs. Placebo","variableRole":"exposure"},{"description":"Change in systolic blood pressure from baseline to 3 months","variableRole":"outcome"}],"studyDesign":[{"coding":[{"system":"https://fevir.net/sevco","code":"SEVCO:01003","display":"randomized assignment"}]}],"statistic":[{"statisticType":{"coding":[{"system":"https://fevir.net/sevco","code":"STATO:0000457","display":"difference in means"}]},"modelCharacteristic":[{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/statistic-model-include-if","extension":[{"url":"attribute","valueCodeableConcept":{"text":"data distribution"}},{"url":"value","valueCodeableConcept":{"text":"normal distribution (Shapiro-Wilk test with p-value \u003e\u003d 0.05)"}}]}],"code":{"text":"Welch\u0027s 2-sample t-test"},"intended":true},{"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/statistic-model-include-if","extension":[{"url":"attribute","valueCodeableConcept":{"text":"data distribution"}},{"url":"value","valueCodeableConcept":{"text":"not consistent with normal distribution (Shapiro-Wilk test with p-value \u003c 0.05)"}}]}],"code":{"text":"Wilcoxon Mann-Whitney test"},"intended":true}]}]}
{"resourceType":"Evidence","id":"example-stroke-0-3-alteplase-vs-no-alteplase-mRS3-6","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\n      \n      \u003cp\u003e\n        \u0026quot;Effect of Alteplase vs No alteplase on mRS 3-6 at 90 days in Stroke 0-3 hours prior\u0026quot; is a comparative effect estimate.\n      \u003c/p\u003e\n\t\n    \u003c/div\u003e"},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/structuredefinition-wg","valueCode":"cds"}],"url":"http://hl7.org/fhir/Evidence/example-stroke-0-3-alteplase-vs-no-alteplase-mRS3-6","identifier":[{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113883.4.642.10.5"}],"name":"EffectOfAlteplaseVsNoAlteplaseOnMRS36At90DaysInStroke03HoursPrior","title":"Effect of Alteplase vs No alteplase on mRS 3-6 at 90 days in Stroke 0-3 hours prior","status":"draft","publisher":"HL7 International / Clinical Decision Support","contact":[{"telecom":[{"system":"url","value":"http://www.hl7.org/Special/committees/dss"}]}],"relatesTo":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/artifact-relationship-type","code":"cites","display":"Cites"}]},"targetMarkdown":"Analysis 1.16 from Wardlaw 2014 \u003cb\u003eCitation:\u003c/b\u003e Wardlaw JM, Murray V, Berge E, del Zoppo GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2014 Jul 29(7):CD000213. PMID 25072528 \u003cb\u003eURL:\u003c/b\u003e https://doi.org/10.1002/14651858.CD000213.pub3"}],"description":"mRS 3-6 at 90 days Odds Ratio 0.65 for Alteplase vs. No Alteplase in patients with acute ischemic stroke 0-3 hours prior","variableDefinition":[{"variableRole":"population","observed":{"reference":"EvidenceVariable/Wardlaw2014Analysis1.16.3EvidenceSet","type":"EvidenceVariable","display":"Wardlaw 2014 Analysis 1.16.3 Evidence set"},"intended":{"reference":"Group/AcuteIschemicStroke0-3Hours","type":"Group","display":"stroke at 0-3 hours"}},{"variableRole":"outcome","observed":{"reference":"EvidenceVariable/example-mRS3-6-at-90days","type":"EvidenceVariable","display":"mRS 3-6 at 90 days"},"intended":{"reference":"EvidenceVariable/example-dead-or-dependent-90day","type":"EvidenceVariable","display":"Dead or functionally dependent at 90 days"}},{"variableRole":"exposure","comparatorCategory":"No Alteplase","observed":{"reference":"EvidenceVariable/example-group-assignment-alteplase-for-stroke-vs-no-alteplase","type":"EvidenceVariable","display":"Group Assignment: Alteplase for Stroke vs No Alteplase"}}],"synthesisType":[{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/synthesis-type","code":"std-MA","display":"summary data meta-analysis"}]}],"studyDesign":[{"coding":[{"system":"https://fevir.net/sevco","code":"SEVCO:01003","display":"randomized assignment"}]}],"statistic":[{"statisticType":{"coding":[{"system":"https://fevir.net/sevco","code":"STATO:0000182","display":"odds ratio"}]},"quantity":{"value":0.65},"numberOfEvents":1137,"sampleSize":{"numberOfStudies":6,"numberOfParticipants":1779},"attributeEstimate":[{"description":"95% CI 0.54 to 0.80","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/attribute-estimate-type","code":"C53324","display":"Confidence interval"}]},"level":0.95,"range":{"low":{"value":0.54},"high":{"value":0.8}}},{"description":"P-value \u003d 0.000023","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/attribute-estimate-type","code":"C44185","display":"P-value"}]},"quantity":{"value":0.000023}},{"description":"Heterogeneity I-sq \u003d 0.0%","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/attribute-estimate-type","code":"0000420","display":"I-squared"}]},"quantity":{"value":0,"unit":"%","system":"http://unitsofmeasure.org","code":"%"}}]}],"certainty":[{"description":"Moderate certainty due to risk of bias","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/certainty-type","code":"Overall","display":"Overall certainty"}]},"rating":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/certainty-rating","code":"moderate","display":"Moderate quality"}]},"subcomponent":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/certainty-type","code":"PublicationBias","display":"Publication bias"}]},"rating":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/certainty-rating","code":"no-concern","display":"no serious concern"}]}},{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/certainty-type","code":"Inconsistency","display":"Inconsistency"}]},"rating":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/certainty-rating","code":"no-concern","display":"no serious concern"}]}},{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/certainty-type","code":"Imprecision","display":"Imprecision"}]},"rating":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/certainty-rating","code":"no-concern","display":"no serious concern"}]}},{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/certainty-type","code":"Indirectness","display":"Indirectness"}]},"rating":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/certainty-rating","code":"no-concern","display":"no serious concern"}]}},{"note":[{"text":"results largely influenced by IST-3 trial which was unblinded and NINDS trial which had allocation concealment not stated and baseline imbalances"}],"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/certainty-type","code":"RiskOfBias","display":"Risk of bias"}]},"rating":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/certainty-rating","code":"serious-concern","display":"serious concern"}]}}]}]}
{"resourceType":"Evidence","id":"example-ASTRAL-12-alteplase-mRS3-6","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\n      \n      \u003cp\u003e\n        \u0026quot;Risk of mRS3-6 at 90 days after Alteplase for Stroke if ASTRAL score 12\u0026quot; is a univariate risk estimate (non-comparative evidence).\n      \u003c/p\u003e\n\t\n    \u003c/div\u003e"},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/structuredefinition-wg","valueCode":"cds"}],"url":"http://hl7.org/fhir/Evidence/example-ASTRAL-12-alteplase-mRS3-6","identifier":[{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113883.4.642.10.2"}],"name":"RiskOfMRS36At90DaysAfterAlteplaseForStrokeIfASTRALScore12","title":"Risk of mRS3-6 at 90 days after Alteplase for Stroke if ASTRAL score 12","status":"draft","publisher":"HL7 International / Clinical Decision Support","contact":[{"telecom":[{"system":"url","value":"http://www.hl7.org/Special/committees/dss"}]}],"relatesTo":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/artifact-relationship-type","code":"cites","display":"Cites"}]},"targetMarkdown":"External Validation of the ASTRAL and DRAGON Scores for Prediction of Functional Outcome in Stroke. \u003cb\u003eCitation:\u003c/b\u003e Cooray C, Mazya M, Bottai M, Dorado L, Skoda O, Toni D, Ford GA, Wahlgren N, Ahmed N. External Validation of the ASTRAL and DRAGON Scores for Prediction of Functional Outcome in Stroke. Stroke. 2016 Jun;47(6):1493-9. Epub 2016 May 12. PMID 27174528 \u003cb\u003eURL:\u003c/b\u003e https://doi.org/10.1161/STROKEAHA.116.012802"}],"description":"5.3% risk of mRS 3-6 at 90 days","variableDefinition":[{"variableRole":"population","observed":{"reference":"Group/ASTRAL-Cooray-validation-cohort-and-received-alteplase","type":"Group","display":"ASTRAL validation cohort and received alteplase"},"intended":{"reference":"Group/ASTRAL-12-and-received-alteplase","type":"Group","display":"patients 0-4.5 hours after acute ischemic stroke onset with ASTRAL score \u003d 12 and received alteplase"}},{"description":"functionally dependent or dead at 3 months","variableRole":"outcome","observed":{"reference":"EvidenceVariable/example-mRS3-6-at-90days","type":"EvidenceVariable","display":"mRS 3-6 at 90 days"},"intended":{"reference":"EvidenceVariable/example-dead-or-dependent-90day","type":"EvidenceVariable","display":"Dead or functionally dependent at 90 days"},"directnessMatch":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/directness","code":"high","display":"High quality match between observed and intended variable"}]}}],"studyDesign":[{"coding":[{"system":"https://fevir.net/sevco","code":"SEVCO:01016","display":"Uncontrolled cohort design"}]}],"statistic":[{"description":"5.3% risk","statisticType":{"coding":[{"system":"https://fevir.net/sevco","code":"STATO:0000607","display":"proportion"}],"text":"derived proportion"},"quantity":{"value":0.0525},"sampleSize":{"note":[{"text":"number of participants describes number in the total study sample, known data count describes number in study sample with ASTRALscore \u003d 12, total number of events describes number of participants with ASTRAL score \u003d 12 and outcome of mRS 3-6 at 90 days"}],"numberOfParticipants":36131}}],"certainty":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/certainty-type","code":"Overall","display":"Overall certainty"}]},"rating":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/certainty-rating","code":"high","display":"High quality"}]},"subcomponent":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/certainty-type","code":"RiskOfBias","display":"Risk of bias"}]},"rating":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/certainty-rating","code":"no-concern","display":"no serious concern"}]}},{"description":"Estimated risk from validation calibration plot consistent with predicted risk; observed risk in subgroup with ASTRAL score \u003d 12 consistent with validation calibration plot","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/certainty-type","code":"Inconsistency","display":"Inconsistency"}]},"rating":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/certainty-rating","code":"no-concern","display":"no serious concern"}]}},{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/certainty-type","code":"Indirectness","display":"Indirectness"}]},"rating":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/certainty-rating","code":"no-concern","display":"no serious concern"}]}},{"description":"Narrow confidence interval","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/certainty-type","code":"Imprecision","display":"Imprecision"}]},"rating":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/certainty-rating","code":"no-concern","display":"no serious concern"}]}},{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/certainty-type","code":"PublicationBias","display":"Publication bias"}]},"rating":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/certainty-rating","code":"no-concern","display":"no serious concern"}]}}]}]}
{"resourceType":"Evidence","id":"example-death-or-major-injury-reduce-parachute-vs-empty-backpack","meta":{"versionId":"6","lastUpdated":"2025-02-17T13:56:56.719Z","profile":["http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence","http://hl7.org/fhir/uv/ebm/StructureDefinition/single-study-evidence"]},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/structuredefinition-wg","valueCode":"cds"}],"url":"http://hl7.org/fhir/Evidence/example-death-or-major-injury-reduce-parachute-vs-empty-backpack","identifier":[{"type":{"text":"FEvIR Object Identifier"},"system":"urn:ietf:rfc:3986","value":"https://fevir.net/FOI/318273","assigner":{"display":"Computable Publishing LLC"}}],"title":"Death or Major Traumatic Injury on Impact comparing intervention vs. comparator","citeAs":"Death or Major Traumatic Injury on Impact comparing intervention vs. comparator [Database Entry: FHIR Evidence Resource]. Contributors: Joanne Dehnbostel [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 318273. Revised 2025-02-17. Available at: https://fevir.net/resources/Evidence/318273. Computable resource at: https://fevir.net/resources/Evidence/318273#json.","status":"active","author":[{"name":"Joanne Dehnbostel"}],"publisher":"HL7 International / Clinical Decision Support","contact":[{"telecom":[{"system":"url","value":"http://www.hl7.org/Special/committees/dss"}]}],"copyright":"https://creativecommons.org/licenses/by-nc-sa/4.0/","relatesTo":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/artifact-relationship-type","code":"part-of","display":"Part Of"}]},"targetReference":{"reference":"Composition/312172","type":"Composition","display":"PARACHUTE Trial Results"}}],"description":"Example Evidence Resource for EBMonFHIR IG using SingleStudyEvidence and ComparativeEvidence Profiles","variableDefinition":[{"variableRole":"population","observed":{"reference":"Group/292955","type":"Group","display":"PARACHUTE Trial Participants"}},{"variableRole":"exposure","comparatorCategory":"Parachute trial participants assigned an empty backpack","observed":{"reference":"EvidenceVariable/297490","type":"EvidenceVariable","display":"GroupAssignment: Jumping from aircraft with parachute vs. Jumping from aircraft with empty backpack"}},{"variableRole":"outcome","observed":{"reference":"EvidenceVariable/297743","type":"EvidenceVariable","display":"Death or Major Traumatic Injury on Impact"}}],"synthesisType":[{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/synthesis-type","code":"NotApplicable","display":"not applicable"}]}],"studyDesign":[{"coding":[{"system":"https://fevir.net/sevco","code":"SEVCO:01003","display":"randomized assignment"}]}],"statistic":[{"statisticType":{"coding":[{"system":"https://fevir.net/sevco","code":"STATO:0000614","display":"absolute difference"}]},"quantity":{"value":0},"sampleSize":{"knownDataCount":23},"attributeEstimate":[{"type":{"coding":[{"system":"https://fevir.net/sevco","code":"STATO:0000700","display":"p-value"}]},"quantity":{"value":0.9,"comparator":"\u003e"}}]}]}
{"resourceType":"Evidence","id":"example-stroke-alteplase-fatalICH","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\n      \n      \u003cp\u003e\n        \u0026quot;Risk of fatal ICH with alteplase for stroke\u0026quot; is a univariate risk estimate.\n      \u003c/p\u003e\n\t\n    \u003c/div\u003e"},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/structuredefinition-wg","valueCode":"cds"}],"url":"http://hl7.org/fhir/Evidence/example-stroke-alteplase-fatalICH","identifier":[{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113883.4.642.10.1"}],"name":"RiskOfFatalICHWithAlteplaseForStroke","title":"Risk of fatal ICH with alteplase for stroke","status":"draft","publisher":"HL7 International / Clinical Decision Support","contact":[{"telecom":[{"system":"url","value":"http://www.hl7.org/Special/committees/dss"}]}],"relatesTo":[{"type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/artifact-relationship-type","code":"cites","display":"Cites"}]},"targetMarkdown":"Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. \u003cb\u003eCitation:\u003c/b\u003e Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al;Stroke Thrombolysis Trialists\u0027 Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014 Nov 29;384(9958):1929-35 PMID 25106063 \u003cb\u003eURL:\u003c/b\u003e https://doi.org/10.1016/S0140-6736(14)60584-5"}],"description":"2.7% incidence of fatal intracranial hemorrhage within 7 days with alteplase in patients with acute ischemic stroke","variableDefinition":[{"variableRole":"population","observed":{"reference":"Group/Emberson-2014-IPD-MA-Alteplase-Cohort","type":"Group","display":"Emberson 2014 IPD-MA Alteplase Cohort"},"intended":{"reference":"Group/AcuteIschemicStrokeTreatedWithAlteplase","type":"Group","display":"adults with acute ischemic stroke treated with alteplase"}},{"variableRole":"outcome","observed":{"reference":"EvidenceVariable/example-fatal-ICH-in-7-days","type":"EvidenceVariable","display":"fatal ICH"},"intended":{"reference":"EvidenceVariable/example-fatal-ICH-in-7-days","type":"EvidenceVariable","display":"fatal ICH"}}],"synthesisType":[{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/synthesis-type","code":"IPD-MA","display":"individual patient data meta-analysis"}]}],"studyDesign":[{"coding":[{"system":"https://fevir.net/sevco","code":"SEVCO:01003","display":"randomized assignment"}]}],"statistic":[{"statisticType":{"coding":[{"system":"https://fevir.net/sevco","code":"STATO:0000607","display":"proportion"}]},"quantity":{"value":0.026835741669},"numberOfEvents":91,"sampleSize":{"numberOfStudies":9,"numberOfParticipants":3391}}]}